“Convergence of AI and Biology: Companies at the Forefront of Transformative Innovations”:- $IPA, $MRKR, $PRAX, $RMED
https://www.digitaljournal.com/pr/news/getnew...-prax-rmed
This article examines promising small-cap companies in the biotech sector for potential investments.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) - The company is now being seen as something great due to its innovative approach to bringing the power of artificial intelligence to drug discovery. In fact, it has even been suggested that it could be to drug discovery what Amazon (NASDAQ:AMZN) is to e-commerce or Microsoft (NASDAQ:MSFT) is to software.
Although the company appears to have a technology that is superior to many of its competitors, the stock has not gotten as much attention and the liquidity is negligible. It is a stock that could provide an opportunity for investors to get into a highly innovative company at an early stage and hope to get handsome returns in the long run if things work out.
The company has brought about a revolutionary change in the field of drug discovery through its artificial intelligence-powered platform LENS. The platform had been developed by BioStrand, a subsidiary unit of ImmunoPrecise Antibodies.
The platform is based on HYFT technology which works as the semantic source input for the Large Language Models (LLMs) which are used in LENS.
On June 13 the company announced that its subsidiary unit BioStrand had been successful in discovering a new use case for the Information Integration Dilemma (IID).
Marker Therapeutics Inc (NASDAQ:MRKR) - Clinical stage immune-oncology firm Marker Therapeutics Inc is involved in the commercialization and development of a range of T-Cell-based immunotherapies. These immunotherapies are meant for treating hematological malignancies and solid tumors.
It serves the United States market. On June 12 the company announced that the very first patient had been treated with as part of the Phase 1 multicenter APOLLO trial investigating MT-601 which is being sponsored by Market Therapeutics. The product in question is a multi-tumor associated antigen specific T-cell product which targets 6 antigens. The product is meant for the treatment of patients suffering from lymphoma who were either ineligible or had failed to get treated by anti-CD19 CAR T cell treatment.
Praxis Precision Medicines Inc (NASDAQ
RAX) - Clinical stage biopharmaceutical firm Praxis Precision Medicines Inc is engaged in the development of therapies for disorders of the central nervous system, which are characterized by neuronal excitation-inhibition imbalance.
On June 15 the company announced that it had set the price of its underwritten public offering of 55,150,000 shares of its common stock for the price of $0.95 each. The company expects the gross proceeds from the transaction to be $59.1 million after deductions for commissions, underwriting discounts, and the pre-funded warrants that the company would offer.
Ra Medical Systems Inc (NYSEAMERICAN:RMED) - The company along with its fully owned subsidiary unit Catheter Precision, an innovative medical devices company, are involved in introducing new solutions to the market targeted at improving the treatment of cardiac arrhythmias. Ra Medical Systems is involved in developing path-breaking technology meant for electrophysiology procedures through constant consultation with physicians.
Last week the company announced that the first customer of Catheter Precision Heart Hospital of New Mexico at Lovelace Medical Center had completed 100 ventricular ablation procedures through the deployment of VIVO. VIVO is a 3D imaging non-invasive system from Catheter Precision that helps in identifying the earliest electrical activation of ventricular arrhythmias.
https://www.digitaljournal.com/pr/news/getnew...-prax-rmed
This article examines promising small-cap companies in the biotech sector for potential investments.
ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) - The company is now being seen as something great due to its innovative approach to bringing the power of artificial intelligence to drug discovery. In fact, it has even been suggested that it could be to drug discovery what Amazon (NASDAQ:AMZN) is to e-commerce or Microsoft (NASDAQ:MSFT) is to software.
Although the company appears to have a technology that is superior to many of its competitors, the stock has not gotten as much attention and the liquidity is negligible. It is a stock that could provide an opportunity for investors to get into a highly innovative company at an early stage and hope to get handsome returns in the long run if things work out.
The company has brought about a revolutionary change in the field of drug discovery through its artificial intelligence-powered platform LENS. The platform had been developed by BioStrand, a subsidiary unit of ImmunoPrecise Antibodies.
The platform is based on HYFT technology which works as the semantic source input for the Large Language Models (LLMs) which are used in LENS.
On June 13 the company announced that its subsidiary unit BioStrand had been successful in discovering a new use case for the Information Integration Dilemma (IID).
Marker Therapeutics Inc (NASDAQ:MRKR) - Clinical stage immune-oncology firm Marker Therapeutics Inc is involved in the commercialization and development of a range of T-Cell-based immunotherapies. These immunotherapies are meant for treating hematological malignancies and solid tumors.
It serves the United States market. On June 12 the company announced that the very first patient had been treated with as part of the Phase 1 multicenter APOLLO trial investigating MT-601 which is being sponsored by Market Therapeutics. The product in question is a multi-tumor associated antigen specific T-cell product which targets 6 antigens. The product is meant for the treatment of patients suffering from lymphoma who were either ineligible or had failed to get treated by anti-CD19 CAR T cell treatment.
Praxis Precision Medicines Inc (NASDAQ
RAX) - Clinical stage biopharmaceutical firm Praxis Precision Medicines Inc is engaged in the development of therapies for disorders of the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. On June 15 the company announced that it had set the price of its underwritten public offering of 55,150,000 shares of its common stock for the price of $0.95 each. The company expects the gross proceeds from the transaction to be $59.1 million after deductions for commissions, underwriting discounts, and the pre-funded warrants that the company would offer.
Ra Medical Systems Inc (NYSEAMERICAN:RMED) - The company along with its fully owned subsidiary unit Catheter Precision, an innovative medical devices company, are involved in introducing new solutions to the market targeted at improving the treatment of cardiac arrhythmias. Ra Medical Systems is involved in developing path-breaking technology meant for electrophysiology procedures through constant consultation with physicians.
Last week the company announced that the first customer of Catheter Precision Heart Hospital of New Mexico at Lovelace Medical Center had completed 100 ventricular ablation procedures through the deployment of VIVO. VIVO is a 3D imaging non-invasive system from Catheter Precision that helps in identifying the earliest electrical activation of ventricular arrhythmias.
